Finance

Lists
Outlook: 23.3% bullish·20.0% bearish
Go to analysis
CVS:NYSE
CVS Health Corp
$92.68
+0.34%
(+0.31) 1D
$92.68
0.00% (0.00)
After hours
Closed: Oct 19, 4:00:08 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CVS...
Open
$91.60
High
$92.74
Low
$91.03
Mkt. cap
118.53B
Avg. vol.
8.75M
Volume
5.38M
Dividend
2.87%
Quarterly dividend
$0.67
Ex-dividend date
Oct 22, 2026
P/E ratio
24.57
52-wk high
$110.68
52-wk low
$69.51
EPS
$3.77
Beta
0.60
Shares outstanding
1.28B
No. of employees
260K
Open
$91.60
High
$92.74
Low
$91.03
Mkt. cap
118.53B
Avg. vol.
8.75M
Volume
5.38M
Dividend
2.87%
Quarterly dividend
$0.67
Ex-dividend date
Oct 22, 2026
P/E ratio
24.57
52-wk high
$110.68
52-wk low
$69.51
EPS
$3.77
Beta
0.60
Shares outstanding
1.28B
No. of employees
260K
News stories
From web sources and news partners
Profile
CVS Health Corporation is an American multinational healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider, among many other brands. The company is the world's second largest healthcare company, behind UnitedHealth Group. In 2023, the company was ranked 64th in the Forbes Global 2000. CVS started in Lowell, Massachusetts by brothers Stanley and Sidney Goldstein and their partner Ralph Hoagland. The name stood for Consumer Value Stores. Wikipedia
About CVS Health Corp
CEODavid Joyner
Employees260K
Founded1963
HeadquartersWoonsocket, Rhode Island, United States
SectorHealth care provider
Websitecvshealth.com
Analyst ratings
Based on 17 analysts giving stock ratings to CVS in the past 3 months
Strong buy
Buy
17
Hold
0
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for CVS in the last 3 months.
Highest
Current $92.68
$125.00 (+34.87%)
Average
$114.59 (+23.64%)
Lowest
$107.00 (+15.45%)
Analyst
Recommendation
Action
Price target
Projected
Date
Allen Lutz
Bank of America Securities
Buy
Maintained
$110.00
+18.7%
10/13/2026
Michael Cherny
Leerink Partners
Buy
Reiterated
$112.00
+20.8%
10/12/2026
Charles Rhyee
TD Cowen
Buy
Maintained
$110.00
+18.7%
10/09/2026
Ben Hendrix
RBC Capital
Buy
Maintained
$113.00
+21.9%
10/07/2026
Lance Wilkes
Bernstein
Buy
Maintained
$112.00
+20.8%
10/05/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
$125.00
+34.9%
10/02/2026
Stephen Baxter
Wells Fargo
Buy
Maintained
$123.00
+32.7%
09/15/2026
Kevin Caliendo
UBS
Buy
Reiterated
$118.00
+27.3%
09/03/2026
Brian Tanquilut
Jefferies
Buy
Maintained
$120.00
+29.5%
08/31/2026
Jessica Tassan
Piper Sandler
Buy
Maintained
$113.00
+21.9%
08/26/2026
Steven Silver
Argus Research
Buy
Maintained
$114.00
+23%
08/18/2026
Lisa Gill
J.P. Morgan
Buy
Maintained
$118.00
+27.3%
08/12/2026
Erin Wright
Morgan Stanley
Buy
Reiterated
$111.00
+19.8%
08/10/2026
Michael Ha
Robert W. Baird
Buy
Maintained
$107.00
+15.5%
08/06/2026
David S Macdonald
Truist Financial
Buy
Reiterated
$118.00
+27.3%
08/06/2026
Andrew Mok CFA
Barclays
Buy
Maintained
$108.00
+16.5%
08/06/2026
Scott Fidel
Goldman Sachs
Buy
Maintained
$116.00
+25.2%
07/27/2026
Ann Hynes
Mizuho Securities
Buy
Maintained
$120.00
+29.5%
07/13/2026
Sarah James
Cantor Fitzgerald
Buy
Maintained
$110.00
+18.7%
07/07/2026
Rajesh Kumar
HSBC
Hold
Maintained
$103.00
+11.1%
07/06/2026
George Hill
Deutsche Bank
Buy
Maintained
$92.00
-0.7%
05/07/2026
Courtney Breen
Bernstein
Buy
Maintained
$94.00
+1.4%
03/30/2026
Unknown Analyst
Oppenheimer
Hold
Reiterated
-
-
02/11/2026
Last report
Aug 5, 2026
Fiscal period
Q2 2026
$2.58 / $1.85
+39.36%beat
Revenue / Est. (USD)
105.46B / 100.09B
+5.36%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
102.24B
105.10B
99.85B
105.46B
Cost of goods sold
89.06B
92.13B
84.80B
90.35B
Cost of revenue
89.06B
92.13B
84.80B
90.35B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.86B
11.32B
10.93B
11.04B
Operating expense
10.86B
11.32B
10.93B
11.04B
Total operating expenses
99.92B
103.45B
95.73B
101.38B
Operating income
2.32B
1.65B
4.12B
4.07B
Other non operating income
26.00M
-88.00M
32.00M
31.00M
EBT including unusual items
-3.48B
1.35B
3.94B
3.98B
EBT excluding unusual items
2.19B
1.37B
3.95B
3.99B
Income tax expense
508.00M
-1.57B
981.00M
982.00M
Effective tax rate
-14.59%
-115.88%
24.91%
24.69%
Other operating expenses
-
-
-
-
Net income
-3.98B
2.94B
2.94B
2.98B
Net profit margin
-3.89%
2.80%
2.95%
2.82%
Earnings per share
1.60
1.09
2.57
2.58
Interest and investment income
632.00M
594.00M
574.00M
641.00M
Interest expense
-784.00M
-787.00M
-774.00M
-757.00M
Net interest expenses
-152.00M
-193.00M
-200.00M
-116.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
3.45B
2.80B
5.23B
5.20B
Gain or loss from assets sale
-483.00M
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps